Related coverage linked through entity extraction aliases.
May 14, 2026
Biotech M&A is shifting toward late-stage CNS and oncology assets with human clinical validation. Oncotelic Therapeutics said it advanced global IP protection for OT-101 and CNS drug delivery.
May 12, 2026
A 2026 review outlines the shift in solid organ transplantation from broad immunosuppression to Treg-based active tolerance. It covers polyclonal Tregs, CAR-Tregs and CRISPR-edited off-the-shelf products.
Apr 29, 2026
Single-cell RNA sequencing of nearly 92,000 cells from the DESTINY-Gastric06 trial reveals distinct primary and acquired resistance mechanisms to trastuzumab deruxtecan in HER2-positive gastric cancer, including MUC3A and CST3 as key drivers.
Apr 04, 2026
Experimental topical therapies for diabetic foot ulcers are showing early promise. Studies described probiotic-based treatments, a medieval antimicrobial mixture and a quercetin-loaded hyaluosome gel with anti-inflammatory and wound-healing effects.
Mar 25, 2026
Diamyd Medical anticipates March 2026 interim results from its Phase 3 diabetes trial that could support a BLA pathway. Capricor Therapeutics awaits an August 2026 FDA decision on its Duchenne muscular dystrophy treatment BLA. Bicara Therapeutics prepares for Phase 3 study initiation of its oncology candidate toward future BLA submission.
Mar 25, 2026
The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.
Mar 16, 2026
HCW Biologics regained compliance with Nasdaq listing rules and completed a follow-on offering priced at $0.6055 per unit to raise approximately $1.5 million for clinical development of immunotherapies targeting chronic inflammation.
Mar 13, 2026
The blood-brain barrier continues to block most treatments for glioblastoma and central nervous system diseases, with only 0.01% of biologic drugs reaching the brain. New intellectual property coverage and synthetic methods aim to address delivery challenges.
Mar 11, 2026
Researchers at the Regina Elena National Cancer Institute in Rome discovered how the hMENA protein enables non-small cell lung cancer to resist immunotherapy by regulating cancer-associated fibroblasts that create a protective tumor microenvironment.
Feb 26, 2026
Researchers have developed a remote-controlled CAR T-cell therapy that can be switched off on demand using venetoclax, while new engineering strategies aim to overcome barriers in treating glioblastoma and other solid tumors.
Feb 17, 2026
Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation over early-stage programs. Oncology and CNS programs have emerged as strategic M&A targets due to large commercial markets and significant unmet medical needs.
